Lanadelumab (SHP643), a humanized IgG1 monoclonal antibody, targets plasma kallikrein (pKal) with a K i value of 0.12 nM, effectively inhibiting both its free form and its interaction with high molecular weight kininogen (HMWK)-bound pKal. This compound shows promise for hereditary angioedema research [1] [2].